

## ICOSAPENT ETHYL capsules (Vazkepa® ▼) for reducing the risk of cardiovascular events

**The Pan Mersey Area Prescribing Committee does not currently recommend the prescribing of ICOSAPENT ETHYL capsules (Vazkepa® ▼) for reducing the risk of cardiovascular events.**

### GREY

Icosapent ethyl is indicated to reduce the risk of cardiovascular events in adult statin-treated patients at high cardiovascular risk with elevated triglycerides ( $\geq 150$  mg/dL [ $\geq 1.7$  mmol/l]) **and**

- > established cardiovascular disease, **or**
- > diabetes, and at least one other cardiovascular risk factor.<sup>[1]</sup>

This recommendation will be reviewed when the [NICE TA](#) is published.

In the meantime, clinicians should continue to follow current national guidance and local formulary choices for lipid modification:

- > NICE Clinical guideline [CG181]: [Cardiovascular disease: risk assessment and reduction, including lipid modification](#) (last updated 27 September 2016)
- > Pan Mersey APC Formulary [Chapter 02.12 Lipid-regulating drugs](#)

### References

1. Amarin Pharmaceuticals Ireland Limited. Summary of Product Characteristics, [Vazkepa](#), 19 October 2021. Accessed 07 February 2022.

**Note:** Patients who are not eligible for treatment under this statement may be considered on an individual basis where their GP or consultant believes exceptional circumstances exist that warrant deviation from the rule of this policy. In this situation, follow locally defined processes.